30
CARDIAC ARRHYTHMIA Stacy Arvinna J, Group 3 KSMU

Antiarrythmia

Embed Size (px)

Citation preview

Page 1: Antiarrythmia

CARDIAC ARRHYTHMIA

Stacy Arvinna J,Group 3KSMU

Page 2: Antiarrythmia

• Types of Arrhythmias– Ventricular

• Cardiac Action Potential• Ion Channels of Interest• Classification of Anti-arrhythmic drugs• Drugs and Re-entry• Class I Drugs• Class III Drugs• Side Effects• Alternative Treatments and Future Drug

Development

TOPICS COVERED

Page 3: Antiarrythmia

MECHANISMS OF CARDIAC ARRHYTHMIAS

1. Enhancement or depression of impulse generation a. Enhanced or depressed normal automaticity from the SA node, b. Abnormal automaticity develop in atrial or ventricular myocardium. c. Triggered activity develop from normally quiescent cardiac tissue peri AV nodal or Purkinje system. due to I.early. afterdepolarizations II.late"af'èé1^depolarízations

2. Abnormal conduction of the cardiac impulse a. Conduction block b. Delayed conduction c. Unídirectional block and reentry or reflection

Page 4: Antiarrythmia
Page 5: Antiarrythmia
Page 6: Antiarrythmia

VENTRICULAR RE-ENTRY

•Abnormal pattern of depolarization through the heart

•Functional•Anatomic

Page 7: Antiarrythmia

THE CARDIAC ACTION POTENTIAL

Page 8: Antiarrythmia

ION CHANNELS RELEVENT TO THE CARDIAC ACTION

POTENTIAL

Page 9: Antiarrythmia

Antiarrhythmic Drug Pathways

Page 10: Antiarrythmia

THE VAUGHAN WILLIAMS CLASSIFICATION SYSTEM OF ANTI-ARRHYTHMIC DRUGS

Class Basic MechanismI-Sodium Channel Blockade

Reduce phase 0 slope and peak of action potential

IA   Moderate reduction in phase 0 slope; increase APD; increase ERP

IB Small reduction in phase 0 slope; reduce APD; decrease ERP

IC Pronounced reduction in phase 0 slope; no effect on APD or ERP

II-Beta-blockade Delay repolarization (phase 3) and thereby increase action potential duration and effective refractory period.

III-potassium-channel blockade

Prolongation of APD and increase ERP; no effect on phase 0

IV-Calcium channel blockade

Block L-type calcium-channels; most effective at SA and AV nodes; reduce rate and conduction.

Page 11: Antiarrythmia
Page 12: Antiarrythmia
Page 13: Antiarrythmia
Page 14: Antiarrythmia

HOW THESE DRUGS AFFECT RE-ENTRY

• Class I: retards conduction enough so that beat still gets through normal cardiac tissue but not through any weakened tissue

• Class III: prolongs refractoriness

Page 15: Antiarrythmia

CLASS I• IA

– moderate

• IB– weakest

• IC– strongest

Page 16: Antiarrythmia

CLASS IA

Page 17: Antiarrythmia

CLASS IA-Procainamide

Procainamide

N-Acetyl Procainamide

Page 18: Antiarrythmia

CLASS IB

Page 19: Antiarrythmia

CLASS IB-Lidocaine

Page 20: Antiarrythmia

CLASS IC

Page 21: Antiarrythmia

CLASS IC-flecainide

Page 22: Antiarrythmia

Cardiac Side Effects-Proarrhythmia

•Potential re-entrant circuit can be turned into an actual re-entrant circuit

• Increased incidence of death in the case of myocardial infarction

Page 23: Antiarrythmia

Class III

Page 24: Antiarrythmia

CLASS III-Sotalol

Page 25: Antiarrythmia

Torsades des Pointes

•Long Q-T syndrome•Polymorhic Ventricular Tachycardia•IA drugs can also cause this

•Blocking of potassium channels and prolonging repolarization

Page 26: Antiarrythmia

ALTERNATIVE TREATMENTS

• Ablation• Implanantable

Cardioverter Defibrillators (ICDs)

Page 27: Antiarrythmia

ICD Placement In the Heart

Page 28: Antiarrythmia

FUTURE OF DRUG DEVELOPMENT

• Drugs with defibrillating effects– Sotalol– Tedisamil

• Sympathomimetic-modulates cAMP • Protects Gap junctions and enhances Ca2+

uptake by SR

• Drugs affecting Ion Channelopathy– hyperphosphorylation

• Drugs or Devices?

Page 29: Antiarrythmia

Antiarrhythmic Drug Pathways

Page 30: Antiarrythmia

• :www.aavpt.org/symposia/documents/Muir213-221.pdf